a Immunology Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.
b Student Research Committee , Tabriz University of Medical Sciences , Tabriz , Iran.
Artif Cells Nanomed Biotechnol. 2017 Nov;45(7):1292-1297. doi: 10.1080/21691401.2016.1261872. Epub 2016 Nov 29.
Despite using lots of progression in hypersensitivity, it is not yet a cure. Current treatment for allergy focuses on two approaches, including treats only the symptoms of allergy by utilizing drugs and the other is desensitization therapy (immunotherapy), which involves administration of specific allergens. The main obstacle to hypersensitivity permanent treatment is the IgE producing subclass of B-lymphocytes which is the source of IgE- producing in hypersensitive patients. Removal of these lymphocytes causes noticeable reduction in the levels of IgE and allergic responses significantly. In this paper, we proposed a novel complementary approach, which we have called the "nano-liposomes-based target toxicity machine (NBTTM)", which controls hypersensitivity by removing the IgE producing B-lymphocytes. In this regard, our proposed nano-liposomes (pollen allergens/Aptamer/SCFV/MIP loaded lipid bilayer enclosing toxin interior) will be able to bind to any IgE markers in the lymphatic circulation. The nano-liposomes will bind to the IgE + atopic B cells and cause cell death by internalizing into B cells.
尽管在超敏反应中使用了很多进展,但它还不是一种治愈方法。目前的过敏治疗主要集中在两种方法上,包括通过药物仅治疗过敏症状和另一种脱敏疗法(免疫疗法),它涉及使用特定的过敏原。超敏反应的永久性治疗的主要障碍是产生 IgE 的 B 淋巴细胞亚群,它是超敏反应患者产生 IgE 的来源。去除这些淋巴细胞会导致 IgE 水平和过敏反应显著降低。在本文中,我们提出了一种新的互补方法,我们称之为“基于纳米脂质体的靶向毒性机 (NBTTM)”,通过去除产生 IgE 的 B 淋巴细胞来控制超敏反应。在这方面,我们提出的纳米脂质体(花粉过敏原/适体/ SCFV/MIP 负载的脂质双层包封毒素内部)将能够与淋巴循环中的任何 IgE 标记结合。纳米脂质体将与 IgE+特应性 B 细胞结合,并通过内化到 B 细胞中导致细胞死亡。